Shawn Cross is Director of Cyclo Therapeutics, Inc.. Currently has a direct ownership of 107,749 shares of CYTH, which is worth approximately $62,494. The most recent transaction as insider was on Nov 15, 2024, when has been sold 17,228 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 108K
19.03% 3M change
n/a 12M change
Total Value Held $62,494

Shawn Cross Transaction History

Date Transaction Value Shares Traded Shares Held Form
Nov 15 2024
BUY
Grant, award, or other acquisition
-
17,228 Added 13.78%
107,749 Common Stock
Aug 16 2024
BUY
Grant, award, or other acquisition
-
9,028 Added 9.07%
90,521 Common Stock
Jun 03 2024
BUY
Grant, award, or other acquisition
-
8,887 Added 9.83%
81,493 Common Stock
Dec 27 2023
BUY
Grant, award, or other acquisition
-
72,606 Added 50.0%
72,606 Common Stock

Also insider at

AMTI
Applied Molecular Transport Inc. Healthcare
PCRX
Pacira BioSciences, Inc. Healthcare
SC

Shawn Cross

Director
South San Francisco, CA

Track Institutional and Insider Activities on CYTH

Follow Cyclo Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CYTH shares.

Notify only if

Insider Trading

Get notified when an Cyclo Therapeutics, Inc. insider buys or sells CYTH shares.

Notify only if

News

Receive news related to Cyclo Therapeutics, Inc.

Track Activities on CYTH